Drospirenone pills carry no greater risk

The results come from the International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC), a prospective study of 85,109 women in the United States and Europe taking drospirenone-21 day, drospirenone-24 day, non-drospirenone or levonorgestrel oral contraceptives.

The study found that over a period of 2–6 years, the overall risk of VTE was about three times (2.9) higher for oral contraceptive users compared to non-pregnant women, but there was no difference in the risk of VTE between the